فهرست نشریات علمی دسترسی آزاد ایران

Objective(s): Our study aimed to demonstrate the therapeutic effects of sacubitril (an inhibitor of neprilysin) and/or valsartan (an ARB) in an experimentally induced polycystic ovary syndrome (PCOS) model and in PCOS-induced insulin resistance.Materials and Methods: After 21 days of letrozole 1 mg/kg administration, rats were confirmed to have PCOS by the vaginal smear method. Following PCOS induction, the experiment was terminated after 15 days of drug treatment. Metformin 300 mg/kg, sacubitril 30 mg/kg, and valsartan 31 mg/kg were administered orally every 15 days. Fasting insulin levels and oral glucose tolerance test (OGTT) were performed to measure insulin resistance and calculate homeostatic model assessment - insulin resistance (HOMA-IR). At the end of the experiment, biochemical analyses were performed on blood samples, and histological studies were conducted on tissue samples.Results: The sacubitril and valsartan combination significantly improved impaired glucose tolerance and HOMA-IR. Serum neprilysin (NEP) levels were found to be significantly higher in the PCOS group than in the healthy group, while atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) levels were found to be significantly lower. The sacubitril+valsartan combination provided the greatest improvement in PCOS-related changes in serum NEP, ANP, BNP, angiotensin II (ANGII), hormone, and lipid levels. The application of sacubitril+valsartan provided an important treatment for insulin resistance due to PCOS by increasing the expression of insulin resistance (IR), insulin receptor substrate 1 (IRS-1), and insulin receptor substrate 2 (IRS-2).Conclusion: Sacubitril and valsartan combination has been shown to have significant therapeutic benefits for PCOS. It markedly reduces cystic follicles and PCOS-associated insulin resistance, improves serum lipid levels, and is supported by pathological findings.